NO753197L - - Google Patents

Info

Publication number
NO753197L
NO753197L NO753197A NO753197A NO753197L NO 753197 L NO753197 L NO 753197L NO 753197 A NO753197 A NO 753197A NO 753197 A NO753197 A NO 753197A NO 753197 L NO753197 L NO 753197L
Authority
NO
Norway
Prior art keywords
formula
acid
compound
compounds
dihydro
Prior art date
Application number
NO753197A
Other languages
Norwegian (no)
Inventor
P Stadler
H Depoortere
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NO753197L publication Critical patent/NO753197L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02Ergot alkaloids of the cyclic peptide type

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Description

Foreliggende oppfinnelse vedrorer en fremgangsmåte for fremstillingThe present invention relates to a method for production

av nye hetrocykliske forbindelser med formel Iof new heterocyclic compounds of formula I

hvori R betyr alkyl med 1-5 karbonatomer. wherein R means alkyl of 1-5 carbon atoms.

R står spesielt for metyl eller.én i a-stillingen til det nitrogen-R stands specifically for methyl or one in the a-position of the nitrogen

atom hvortil R er bundet, forgrenet alkylrest som isoprøpyl.atom to which R is attached, branched alkyl radical such as isopropyl.

Det særegne ved fremgangsmåten i henhold til oppfinnelsen er atThe peculiarity of the method according to the invention is that

a) et reaksjonsdyktig, funksjonelt derivat av en syre med formel II>7 a) a reactive, functional derivative of an acid of formula II>7

hvori R har den ovennevnte betydning, kondenseres med forbindelsen med formel III wherein R has the above meaning, is condensed with the compound of formula III

i saltform eller in salt form or

b) forbindelser med formel IV b) compounds of formula IV

hvori R har den ovennevnte betydning, hydrogeneres i nærvær av en wherein R has the above meaning, is hydrogenated in the presence of a

katalysator.catalyst.

Omsetningen i henhold til fremgangsmåtenThe turnover according to the procedure

a) utgjor en kondensasjonsreaksjon for amider.a) completes a condensation reaction for amides.

Fra ergotkjemien er det kjent hvilke reaksjonsdyktige funksjonelle From ergot chemistry, it is known which reactive functionals

derivater av 9,10-dihydrolysergsyre som kan anvendes ved slike omsetninger og under hvilke betingelser disse omsetninger kan gj ennomfores. derivatives of 9,10-dihydrolysergic acid which can be used in such reactions and under which conditions these reactions can be carried out.

Som r.eaksjonsdyktige funksjonelle derivater av en syre med formel II kan for eksempel anvendes syreklorid-hydrokloridet, syreazidet eller et blandet anhydrid av en syre med formel II med svovelsyre eller trifloureddiksyre. As reactive functional derivatives of an acid of formula II, for example, the acid chloride hydrochloride, the acid azide or a mixed anhydride of an acid of formula II with sulfuric acid or trifluoroacetic acid can be used.

Foretrukket anvender man de reaksjonsdyktige funksjonelle derivater som kan erholdes ved omsetning av en syre med formel II med fra et kloreringsmiddel og N-di (lavere) alkylsubstituert syreamid av en alifatisk karbocylsyre med 1-3 karbonatomer. Som kloreringsmiddel kan anvendes for eksempel thionylklorid, phosgen eller oxalylklorid. For dannelsen av det anvendte amidklorid egnede syreamider nevnes for eksempel dimetylformamid eller dimetylacetamid. The reactive functional derivatives that can be obtained by reacting an acid of formula II with a chlorinating agent and N-di (lower) alkyl substituted acid amide of an aliphatic carboxylic acid with 1-3 carbon atoms are preferably used. For example, thionyl chloride, phosgene or oxalyl chloride can be used as a chlorinating agent. Suitable acid amides for the formation of the amide chloride used are, for example, dimethylformamide or dimethylacetamide.

Fremgangsmåten a) gjennomfores i en organisk losningsmiddelblanding. Egnende løsningsmidler er for eksempel kloroform/...métylenklorid, dimetylformamid eller acetonitril. Method a) is carried out in an organic solvent mixture. Suitable solvents are, for example, chloroform/...methylene chloride, dimethylformamide or acetonitrile.

Man arbeider i nærvær av e-t kondensasjonsmiddel. Hensiktsmessig anvendes tertiere organiske baser, for eksempel trietylamin, men foretrukket pyredin. You work in the presence of e-t condensation agent. Appropriately, tertiary organic bases are used, for example triethylamine, but preferably pyridine.

Omsetningen kan gj ennomf ores ved temperaturer, mellom -30 og +20°C. Man kan arbéideuuhder normal trykk. The turnover can be carried out at temperatures between -30 and +20°C. One can arbéideuuhder normal pressure.

Hensiktsmessig anvendes for hvert et mol av forbindelsen med formel III i saltform 1,2 til 2,4 mol av et reaksjonsdyktig funksjonelt derivat av en syre med formel III. Appropriately, for every one mole of the compound of formula III in salt form, 1.2 to 2.4 moles of a reactive functional derivative of an acid of formula III are used.

For forbindelsen med formel III er den foretrukne saltform hydrokloridet. For the compound of formula III, the preferred salt form is the hydrochloride.

Hydrogeneringen (fremgangsmåten b) kan gjennomfores etter de for hydrogenering av meldroyealkaloider til ergolin I-forbindelser kjente metoder. The hydrogenation (method b) can be carried out according to the methods known for the hydrogenation of meldroye alkaloids to ergoline I compounds.

For eksempel opptas et lysergsyrederivat med formel IV i et under reaksjonsbetingelsene inert løsningsmiddel eller losningsmiddelblanding og tilsettes katalysatoren, for eksempel palladiumklorid eller palladium på aktivkull. For example, a lysergic acid derivative of formula IV is taken up in a solvent or solvent mixture that is inert under the reaction conditions and the catalyst, for example palladium chloride or palladium on activated carbon, is added.

Egnende inertef Vilosmingmidler er for eksempel noytrale løsningsmidler som dioxan, amider av alifatiske karbocylsyrer som dimetylformamid eller også lavere alkanoler. Suitable inert surfactants are, for example, neutral solvents such as dioxane, amides of aliphatic carboxylic acids such as dimethylformamide or lower alkanols.

Hydrogeneringen kan gjennomfores ved romtemperatur eller svakt forhoyet temperatur. Trykket er ikke kritisk og kan variere mellom normaltrykk og omtrent 80 atmosfærer overtrykk. Vanlig arbeider man derfor hensiktsmessig under normaltrykk. The hydrogenation can be carried out at room temperature or a slightly elevated temperature. The pressure is not critical and can vary between normal pressure and approximately 80 atmospheres overpressure. You usually therefore work appropriately under normal pressure.

Etter avsluttet hydrogenopptagelse fraf iltreres katalysatoren. After completion of hydrogen uptake, the catalyst is filtered off.

Forbindelsene med formel I kan foreligge i fri form eller saltform, for eksempel som hydroklorid. The compounds of formula I can be present in free form or salt form, for example as hydrochloride.

Fra de fri baser lar seg påkjent måteutvinne syreaddisjonssalterAcid addition salts can be extracted from the free bases in a known manner

og omvendt.and vice versa.

Av de som utgangsprodukt anvendte forbindelser med formel II er de forbindelser hvori. R står for metyl og etyl tidligere kjent. Of the compounds of formula II used as starting product are those compounds in which. R stands for methyl and ethyl previously known.

De nye forbindelser med formel II kan fremstilles analogt med deThe new compounds of formula II can be prepared analogously to those

for fremstilling av 6-nor-6-etyl-9,10-dihydrolysergsyre beskrevne fremgangsmåter. methods described for the production of 6-nor-6-ethyl-9,10-dihydrolysergic acid.

Forbindelsen med formel III i det folgende kor.tjbe tegnet som aminocyclol - er ny. The compound of formula III in the following cor.tjbe denoted as aminocyclol - is new.

Denne aminocyclol erholdes ved at man fra forbindelsen med formelThis aminocyclol is obtained by starting from the compound of formula

V, W,

hvori står for en selektivt avspaltbar beskyttelsesgruppe av-spalter R^. in which stands for a selectively cleavable protective group de-cleaving R^.

Den selektive avspalting av beskyttelsesgruppen, for eksempel benzyloksykarbonylgruppen, kan g-j ennomf ores analogt med i péptid-kjemien kjente metoder. The selective removal of the protective group, for example the benzyloxycarbonyl group, can be carried out analogously to methods known in peptide chemistry.

Står'R^ for benzyloksykabonylgruppen går man for eksempel frem på fSigende måte: Beskyttelsesgruppen avspaltes ved hydrogenolyse i surt medium. Hydrogeneringen gjennomfores hensiktsmessig i nærvær av en edelmetall— katalysator. Palladium er spesielt egnet for denne reaksjon. Som bærer afor palladium velges for eksempel aktiv kull. Den katalyt-ii . tiske hydrogenolyse gjennomfores under sure betingelser, for eksempel, i nærvær av 1,2 til 1,5 mol.isyre. Egnende reaksjonsmedier er for eksempel blandinger av inerte. organiske løsningsmidler som dimetylformamid med dioksan, eller metanol med tetrahydrofluran, If R^ stands for the benzyloxycarbonyl group, the procedure is, for example, as follows: The protecting group is removed by hydrogenolysis in an acidic medium. The hydrogenation is conveniently carried out in the presence of a noble metal catalyst. Palladium is particularly suitable for this reaction. As a carrier for palladium, activated charcoal is chosen, for example. The catalyst-ii. tical hydrogenolysis is carried out under acidic conditions, for example, in the presence of 1.2 to 1.5 molar hydrochloric acid. Suitable reaction media are, for example, mixtures of inerts. organic solvents such as dimethylformamide with dioxane, or methanol with tetrahydroflurane,

med klorhydrogensyre som syre. Hydrogeneringen gjennomføres hensiktsmessig ved romtemperatur og normaltrykk. with hydrochloric acid as acid. The hydrogenation is conveniently carried out at room temperature and normal pressure.

Forbindelsen med formel V erholdes analogt med kjente metoder, for eksempel fra det tilsvarende syreazid med formel VI. The compound of formula V is obtained analogously by known methods, for example from the corresponding acid azide of formula VI.

Syreazidet med formel VI kan også overfores direkte,ved behandling med tilnærmet den teoretiske mengde vann og syre, for eksempel saltsyre, i et under reaksjonsbetingelsene inert løsningsmiddel i aminocyclolen. The acid azide of formula VI can also be transferred directly, by treatment with approximately the theoretical amount of water and acid, for example hydrochloric acid, in a solvent inert under the reaction conditions in the aminocyclolene.

De ovennevnte aminocyelolsynteser er i prinsippet deltrinn av Curtius-metoden henholdsvis modifikasjoner derav og skjer under anvendelse av forbindelser med formel VII, The above-mentioned aminocellol syntheses are in principle partial steps of the Curtius method or modifications thereof and take place using compounds of formula VII,

hvori R2står for lavere alkyl, for eksempel etyl, som utgangsprodukt. Esterne med formel VII overfores analogt med kjente metoder i deres tilsvarende fri syre, over karbocylkloridet i syreazidet med formel VI, og dette gir etter gjennomføring av de beskrevne forhåndsregler aminocyclolen. in which R2 stands for lower alkyl, for example ethyl, as starting product. The esters of formula VII are transferred analogously to known methods in their corresponding free acid, over the carboxyl chloride in the acid azide of formula VI, and this gives, after carrying out the described preliminary rules, the aminocyclolene.

Fremstillingen med forbindelsene med formel VII kan foretas analogt med kjente metoder under anvendelse av L-isoleucyl-L-prolin-lactam og S+metyl-benzyloksymalonsyremondetylesterklorid som utganga-material. The preparation with the compounds of formula VII can be carried out analogously to known methods using L-isoleucyl-L-proline lactam and S+methyl-benzyloxymalonic acid monoethyl ester chloride as starting material.

Forbindelsene med formel IV kan erholdes analogt med kjente metoder ved omsetning av aminocyclolen med formel rn med et reaksjonsdyktig funksjonelt derivat av den tilsvarende lysergsyre, for eksempel som det fremgår av den eksperimentelle del av denne beskrivelse. The compounds of formula IV can be obtained analogously to known methods by reacting the aminocyclolene of formula rn with a reactive functional derivative of the corresponding lysergic acid, for example as appears from the experimental part of this description.

I den utstrekning fremstillingen av utgangsforbindelsene ikke er be-skrevet er disse kjente eller kan fremstilles etter i og for seg kjente eller analogt med i og for seg kjente metoder. To the extent that the production of the starting compounds is not described, these are known or can be produced according to per se known or analogously to per se known methods.

Forbindelsene med formel I og deres physiologisk tålbare salter utmerker seg ved interessante farmakodynamiske egenskaper og kan folgelig anvendes som legemidler. The compounds of formula I and their physiologically tolerable salts are distinguished by interesting pharmacodynamic properties and can therefore be used as pharmaceuticals.

Ved ikke-narkotiserte rotter med kronisk implanterte EEG-elektroder bevirker de ved oppfinnelsen fremstillbare forbindelser en signifi-kant forlengelse av våkenfåsene, en forkortelse av fasene for dai klassiske og paradoksale sovn og forlengelse av latenstiden til den forste opptreden av paradoksal sovn. In non-anesthetized rats with chronically implanted EEG electrodes, the compounds that can be produced by the invention cause a significant prolongation of the waking phases, a shortening of the phases for then classical and paradoxical sleep and an extension of the latency time to the first appearance of paradoxical sleep.

Videre reduserer de tallet av de med reserpien i katter fremkalte topp-potensialer "corpus geniculatum laterale" (PGO Spikes). Furthermore, they reduce the number of peak potentials "corpus geniculatum laterale" (PGO Spikes) evoked by reserpine in cats.

Disse forandringer er uttrykk for en vigilans forhoyelse. De ved oppfinnelsen fremstillbare forbindelser er derfor indikert for behandling av seribralinsuffiens. These changes are an expression of an increase in vigilance. The compounds that can be prepared by the invention are therefore indicated for the treatment of cerebral insufficiency.

De legemidler, som kan inneholde forbindelsen med formel I i fri form eller i form av dens fysiologisk tålbare addisjonssalter med syrer, kan foreligge for eksempel f form av en losning eller The medicinal products, which may contain the compound of formula I in free form or in the form of its physiologically tolerable addition salts with acids, may be available, for example, in the form of a solution or

tablet som kan fremstilles etter kjente metoder under anvendelse av valige hjelpe- og bærerstoffer. tablet which can be prepared according to known methods using selected excipients and carriers.

I de etterfølgende eksempler er alle temperaturangivelser i grader Celsius. In the following examples, all temperature indications are in degrees Celsius.

EKSEMPEL 1: 2' B- metyl- 51g- sec. butvl- 9, 10- dihydro- ergopeptin.EXAMPLE 1: 2' B- methyl- 51g- sec. butvl-9, 10-dihydro-ergopeptin.

I det folgende benevnt dihydro-6-ergosin.Hereinafter referred to as dihydro-6-ergosine.

I en sulfideringskolbe ble det innfort 300 ml absolutt dimetylformamid, avkjolt til -20°C og ved denne temperatur ble det i lopet av 20 minutter under omroring tildryppet en losning av 12,3 ml 300 ml of absolute dimethylformamide was introduced into a sulphiding flask, cooled to -20°C and at this temperature a solution of 12.3 ml was added dropwise over the course of 20 minutes with stirring

(0, 143 mol) nydestilert oxailylklorid i 65 ml absolutt acetonitril. Den dannede gule suspensjon ble omrort videre i 15 minutter, deretter ble det ved -20°C tildrysset 38,6 g (0,143 mol) vakuumtorret finpulverisert dihydrolysergsyre. Reaksjonsblandingen omrores videre i 30 minutter, idet temperaturen steg. til 0°C. Deretter ble det på nytt avkjolt til -20°C og 143 ml absolutt pyridin ble tildryppet så hurtig som mulig. Deretter ble det tildrysset 31,6 g (0,0713 mol) aminocyclol-hydroklorid ( inneholder . 1 mol krystall-dimetylformamid og ^ mol krys tall-te trahydrof ifcariy. molvekt dermed 442,9), hvorved temperaturen steg til -10°C og det dannet seg en orangebrun tykk suspensjon som ble omrort ennå i en time. For opparbeidelsen ble det på nytt avkjolt til -20°C og tildryppet 200 ml fosfatpuffer med ph 4. Deretter ble reaksjonsblandingen uthelt på 2,6 1 2N sodalosning og ekstrahert tre ganger med metylenklorid. Metylenkloridlosningene ble ettervasket med 700 ml vann, deretter torret med natriumsulfat og inndampet til torrhet på rotasjonsinn-damper. Det ble tilbake en skumaktig harpiks som ble kromatografert på den 15-dobbelté mengde aluminiumoksyd med aktivitet II. Det således erholte nesten rene dihydro-6-ergosin ble omkrystallisert frai metylenklorid/metanol. (0.143 mol) of freshly distilled oxalyl chloride in 65 ml of absolute acetonitrile. The yellow suspension formed was stirred further for 15 minutes, then 38.6 g (0.143 mol) vacuum-dried finely powdered dihydrolysergic acid was sprinkled in at -20°C. The reaction mixture is stirred further for 30 minutes, as the temperature rises. to 0°C. It was then cooled again to -20°C and 143 ml of absolute pyridine was added dropwise as quickly as possible. Then 31.6 g (0.0713 mol) of aminocyclol hydrochloride (contains .1 mol of crystal dimethylformamide and ^ mol of crystalline trahydrof ifcariy. molar weight thus 442.9) was sprinkled in, whereupon the temperature rose to -10°C and an orange-brown thick suspension formed which was stirred for another hour. For the work-up, it was again cooled to -20°C and 200 ml of phosphate buffer with pH 4 was added dropwise. The reaction mixture was then poured into 2.6 1 2N soda solution and extracted three times with methylene chloride. The methylene chloride solutions were washed with 700 ml of water, then dried with sodium sulfate and evaporated to dryness on a rotary evaporator. A foamy resin remained which was chromatographed on the 15-fold amount of alumina with activity II. The almost pure dihydro-6-ergosine thus obtained was recrystallized from methylene chloride/methanol.

Smeltepunkt 180-183°C (spalting), [a]!2-0^ -44° (c== 3, pyridin) Melting point 180-183°C (decomposition), [a]!2-0^ -44° (c== 3, pyridine)

Aminocyclolen ble erholt på folgende måte:The aminocyclolene was obtained as follows:

17,2 g av forbindelsen med formel V (R1= C6H5-CH20-CO)17.2 g of the compound of formula V (R1= C6H5-CH20-CO)

(40 mmol) ble opplost i 90 ml absolutt dimetylformamid og helt inn(40 mmol) was dissolved in 90 ml of absolute dimethylformamide and poured in

i en widmerkolbe, som forst var utspylt med nitrogen- Deretter ble det tilsatt 6 g palladiumkatalysator (10% palladium på kull) in a Widmer flask, which was first flushed out with nitrogen - Then 6 g of palladium catalyst (10% palladium on charcoal) was added

og etterspylt med 80 ml absolutt tetrahydrofuran. Etter tilsetning av 8 ml 6,5 N hydrogenklorid i tetrahydrofuran (52 mmol) ble det hydrogenert med engang. Etter avsluttet hydrogenering (25 minutter) and backwashed with 80 ml of absolute tetrahydrofuran. After adding 8 ml of 6.5 N hydrogen chloride in tetrahydrofuran (52 mmol), it was hydrogenated at once. After completion of hydrogenation (25 minutes)

ble katalysatoren frafiltrert og det ble inndampet på rotasjons-inndamper ved maksimalt 2 5°C i vakuum for fjernelse av tetrahydro^u furan og dimetylformamid. Resten ble lost med 100 ml dimetylformamid, og losningen ble gnidd litt en spatel. Aminocyclolen krystalliserer som hydroklorid med ét mol krystall-dimetylform- the catalyst was filtered off and it was evaporated on a rotary evaporator at a maximum of 25°C in vacuum to remove tetrahydrofuran and dimethylformamide. The residue was dissolved with 100 ml of dimethylformamide, and the solution was slightly rubbed with a spatula. Aminocyclolene crystallizes as hydrochloride with one mole of crystal dimethylform-

amid og ^ mol krystall-tetrahydrofuran og smelter etter filtrering og ettervasking med tetrahyrdofuran ved 122-123°C. amide and ^ mol of crystal tetrahydrofuran and melts after filtration and washing with tetrahydrofuran at 122-123°C.

Under syntesen av forbindelsen med formel V (smeltepunkt 188-189°C) ble det dannet folgende mellomprodukter: During the synthesis of the compound of formula V (melting point 188-189°C), the following intermediates were formed:

- ester med formel VII med R2= C2H5(smeltepunkt 124-125°C)- ester of formula VII with R2= C2H5 (melting point 124-125°C)

- den syre som tilsvarer esteren (smeltepunkt 168jC (spalting)) - the acid corresponding to the ester (melting point 168jC (decomposition))

- syreazidet med formel VI som videre forarbeides direkte.- the acid azide of formula VI which is further processed directly.

EKSEMPEL 2: 6- nor- 6- isopropvl- 2' B- metvl- 5' g- sec. butvl- 9, 10- dihvdro-erqopeptin ( 6- hor- 6- isopropyl- dihvdro- g- erqosin) EXAMPLE 2: 6- nor- 6- isopropvl- 2' B- metvl- 5' g- sec. butvl- 9, 10- dihydro-erqopeptin ( 6- hor- 6- isopropyl- dihydro- g-erqosine)

Det gås frem analogt med eksempel 1, men det anvendes 13,2 g torr 6-nor-6-isoprpyl-dihydrolysergsyre istedet for dihydrolysergsyre og den i overskriften nevnte forbindelse erholdes med smeltepunkt 182-183°C (spalting), [<g>j^<0>= -15,5° (c = 1 metylenklorid). The procedure is analogous to example 1, but 13.2 g dry 6-nor-6-isopropyl-dihydrolysergic acid is used instead of dihydrolysergic acid and the compound mentioned in the title is obtained with a melting point of 182-183°C (cleavage), [<g> j^<0>= -15.5° (c = 1 methylene chloride).

Den som utgangsprodukt anvendte 6-nor-6-isopropyl-9,10-dihydrolysergsyre erholdes for eksempel på folgende måte: a) Alkylering av 6-nor-9,lO-dihydro-lysergsyre-metylester med iso-propylbromid gir 6-nor-6-iisopropyl-9,10-dihydro-lysergsyreme tyles ter som krystalliserer fra etanol i form av fargelose krystaller med smeltepunkt 194°C. tdc\^ ° = -80,2° (c = 0,582 i metylenklord). The 6-nor-6-isopropyl-9,10-dihydrolysergic acid used as starting product is obtained, for example, in the following way: a) Alkylation of 6-nor-9,10-dihydro-lysergic acid methyl ester with isopropyl bromide gives 6-nor- 6-isopropyl-9,10-dihydro-lysergic acid methyl ester which crystallizes from ethanol in the form of colorless crystals with a melting point of 194°C. tdc\^ ° = -80.2° (c = 0.582 in methylene chloride).

b) Forsepning av den under a) erholte ester ved hjelp av natron-b) Saponification of the ester obtained under a) using sodium

lut i metanol/metylenklorid gir 6-nor-6-isopropyl-9,10-dihydrolysergsyre. Speltepunkt 290°C (spaltning) [ccj^^ = -101° (c = 0,6 lye in methanol/methylene chloride gives 6-nor-6-isopropyl-9,10-dihydrolysergic acid. Melting point 290°C (decomposition) [ccj^^ = -101° (c = 0.6

i metanol).in methanol).

EKSEMPEL 3 Dihydro- g- erqosin..EXAMPLE 3 Dihydro-g-erqosin..

5,48 g (0,01 mol) (3-ergosin (smeltepunkt 203-205°C (spating))/Qajp<20>= -140,2° (c = 1 i kloroform) ble lost i 100 ml etylalkohol 5.48 g (0.01 mol) (3-ergosine (melting point 203-205°C (sparing))/Qajp<20>= -140.2° (c = 1 in chloroform) was dissolved in 100 ml of ethyl alcohol

og dimetylformamid og hydrogenert med 2 g palladium-aktivkull-katalysatore (5% palladium) ved normaltrykk og romtemperatur. and dimethylformamide and hydrogenated with 2 g of palladium-activated carbon catalysts (5% palladium) at normal pressure and room temperature.

Etter opptagelse 2,5 1 hydrogen ble reaksjonen mye langsommere og hydrogeneringen ble avbrutt, katalysatoren ble frafiltrert og filt-ratet inndampet til torrhet i vakuum. Resten ble omkrystallisert to ganger fra metylenklorid/metanol hvorved den i overskriften nevnte forbindelse fremkom som .tynnskiktkomatografisk homogent material, smeltepunkt 181-183°C (spalting) ^ajfi^ = -45° (c = 1 i pyridin). After absorption of 2.5 1 hydrogen, the reaction became much slower and the hydrogenation was interrupted, the catalyst was filtered off and the filtrate was evaporated to dryness in vacuo. The residue was recrystallized twice from methylene chloride/methanol whereby the compound mentioned in the title appeared as thin-layer chromatographically homogeneous material, melting point 181-183°C (decomposition) ^ajfi^ = -45° (c = 1 in pyridine).

6-ergosin ble framstilt på folgende måte:6-ergosine was prepared as follows:

24,1 g lysergsyre ble suspendert i 270 ml acetonitril og avkjolt til -20°C. Véd denne temperatur lot man i lopet av ca. 4 minutter tildryppe an blanding av 12,5 ml trifluoreddiksyreanhydrid, 6,88 ml trifluoreddiksyre og 100 ml acetonitril. Det ble etterrort i 5 minutter, ved -20°C ble det tildrysset 26,6 g aminocyclol-hydroklorid og med en gang deretter ved -20°C ble 90 ml pyridin tildryppet så hurtig som mulig, hvorved temperaturen steg til 0°C. Deretter ble det etterrort i \\ time ved 0°C/på nytt avkjolt 24.1 g of lysergic acid was suspended in 270 ml of acetonitrile and cooled to -20°C. At this temperature, over the course of approx. 4 minutes add dropwise a mixture of 12.5 ml of trifluoroacetic anhydride, 6.88 ml of trifluoroacetic acid and 100 ml of acetonitrile. It was stirred for 5 minutes, at -20°C 26.6 g of aminocyclol hydrochloride were sprinkled in and immediately afterwards at -20°C 90 ml of pyridine was added dropwise as quickly as possible, whereby the temperature rose to 0°C. It was then allowed to stand for \\ hour at 0°C/cooled again

til -20°C og tildryppet 2 70 ml fosfatpuffer med ph 4. Deretter ble reaksjonsblandingen uthelt på 11- 2N sodalosning og ekstrahert 3 ganger med etylenklorid. Metylénkloridlosningen ble ettervasket med vann, torret og inndampet. Det ble tilbake et skum som ble renset på den 30-dobbelte mengde aluminiumoksyd med metylenklorid 0,4 til 0,6% metanol. (3-ergosinet ble vasket med metylenklorid/ to -20°C and added dropwise 2 70 ml of phosphate buffer with ph 4. The reaction mixture was then poured into 11-2N soda solution and extracted 3 times with ethylene chloride. The methylene chloride solution was washed with water, dried and evaporated. A foam remained which was purified on the 30-fold amount of alumina with methylene chloride 0.4 to 0.6% methanol. (The 3-ergosine was washed with methylene chloride/

0,6 til 1% metanol fra kolonnen og omkrystallisert fra metylenklorid etylassetat. 0.6 to 1% methanol from the column and recrystallized from methylene chloride ethyl acetate.

Etter omkrystallisering ble 6-ergosinet torret under hoyvakuum. Smeltepunkt 203 til 205°C, [aj^° = +11,1° (c = 3,5 i pyridin) After recrystallization, the 6-ergosine was dried under high vacuum. Melting point 203 to 205°C, [aj^° = +11.1° (c = 3.5 in pyridine)

EKSEMPEL 4; 6- nor- 6 isopropyl- 21B- metvi- 5' g- sec. butvl- 9, 10-dihydro- erqopeptin ( 6- nor- 6- isoprpvl- dihvdro- B- erqosin) EXAMPLE 4; 6- nor- 6 isopropyl- 21B- metvi- 5' g- sec. butvl- 9, 10-dihydro- erqopeptin (6- nor- 6- isoprpvl- dihydro- B- erqosine)

Det gås frem analogt med eksempel 3 og erholdes ved hydrogenering av 6-nor-6-isopropyl-6-ergosin den i overskriften nevnte forbindelse med smeltepunkt 182-183°C (spalting) Proceed analogously to example 3 and obtain by hydrogenation of 6-nor-6-isopropyl-6-ergosine the compound mentioned in the title with melting point 182-183°C (cleavage)

Wq<0>= 15,5° (c = 1 i metylenklorid). Wq<0>= 15.5° (c = 1 in methylene chloride).

Claims (2)

1. Fremgangsmåte for fremstilling av nye hetrocycliske forbinda eiser med formel I, 1. Process for the production of new heterocyclic compounds of formula I, hvori R betyr alkyl med 1-5 karbonatomer, og deres syreaddisjonssalter, karakterisert ved ata) et reaksjonsdyktig funksjonelt derivat av en syre med formel II wherein R means alkyl with 1-5 carbon atoms, and their acid addition salts, characterized by ata) a reactive functional derivative of an acid of formula II hvori R har den ovennevnte betydning, kondenseres med forbindelsen med formel III wherein R has the above meaning, is condensed with the compound with formula III issåltform, ellerb) forbindelsen med formel IV, ice salt form, orb) the compound of formula IV, hvori R har den ovennevnte betydning, hydrogeneres i nærvær av en katalysator og de erholdte forbindål sera med formel I utvinnes i form av baser eller som syreaddisjonssalter.wherein R has the above meaning, is hydrogenated in the presence of a catalyst and the compound sera of formula I obtained are recovered in the form of bases or as acid addition salts. 2. Fremgangsmåte'som angitt i krav 1, karakterisert ved at 2 '|3-metyl-5 1 a-sec.butyl-9,10-dihydro-ergopeptin fremstillies.2. Method as set forth in claim 1, characterized in that 2'|3-methyl-5 1α-sec.butyl-9,10-dihydro-ergopeptin is produced.
NO753197A 1974-09-27 1975-09-19 NO753197L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1308774A CH602765A5 (en) 1974-09-27 1974-09-27

Publications (1)

Publication Number Publication Date
NO753197L true NO753197L (en) 1976-03-30

Family

ID=4389176

Family Applications (1)

Application Number Title Priority Date Filing Date
NO753197A NO753197L (en) 1974-09-27 1975-09-19

Country Status (16)

Country Link
JP (1) JPS5168599A (en)
AU (1) AU506218B2 (en)
BE (1) BE833835A (en)
CH (1) CH602765A5 (en)
DD (1) DD122532A5 (en)
DE (1) DE2541426A1 (en)
DK (1) DK420375A (en)
ES (1) ES441257A1 (en)
FI (1) FI752616A (en)
FR (1) FR2285885A1 (en)
GB (1) GB1519505A (en)
IL (1) IL48179A (en)
NL (1) NL7511178A (en)
NO (1) NO753197L (en)
SE (1) SE7510552L (en)
ZA (1) ZA756129B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU40275B (en) * 1976-03-04 1985-12-31 Lek Tovarna Farmacevtskih Process for preparing 9,10-dihydro-ergosine and physiologically tolerated acid addition salts thereof
CH649300A5 (en) * 1981-08-07 1985-05-15 Sandoz Ag ERGOPEPTIN DERIVATIVES, THEIR PRODUCTION AND USE.
DE3303616A1 (en) * 1982-02-12 1983-08-25 Sandoz-Patent-GmbH, 7850 Lörrach MOTHER CORNAL CALOIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
BE895842A (en) * 1982-02-12 1983-08-08 Sandoz Sa NOVEL ERGOPEPTIDE ALKALOIDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314959A (en) * 1961-05-10 1967-04-18 Sandoz Ltd Intermediates for the synthesis of ergot alkaloids
CH505102A (en) * 1967-11-01 1971-03-31 Sandoz Ag New ergot alkaloids

Also Published As

Publication number Publication date
DK420375A (en) 1976-03-28
ZA756129B (en) 1977-04-27
JPS5168599A (en) 1976-06-14
AU8520075A (en) 1977-03-31
FR2285885B1 (en) 1979-09-14
IL48179A0 (en) 1975-11-25
DD122532A5 (en) 1976-10-12
FI752616A (en) 1976-03-28
FR2285885A1 (en) 1976-04-23
SE7510552L (en) 1976-03-29
AU506218B2 (en) 1979-12-20
NL7511178A (en) 1976-03-30
DE2541426A1 (en) 1976-04-15
GB1519505A (en) 1978-07-26
CH602765A5 (en) 1978-07-31
BE833835A (en) 1976-03-25
IL48179A (en) 1978-06-15
ES441257A1 (en) 1977-07-01

Similar Documents

Publication Publication Date Title
EP0399814A2 (en) Phenol derivatives for promoting human nerve growth factor
NO753197L (en)
AU612000B2 (en) A process for the preparation of pyrrolidone derivatives
NO744175L (en)
US4247704A (en) Hexahydro thieno imadazole intermediates for the synthesis of biotin
HU218274B (en) N,n&#39;-bis hydroxyalkyl and alkoxyalkyl-pyridine-2,4-dicarboxylic acid diamide derivatives and pharmaceutical compositions comprising such compounds and process for producing them
KR100324040B1 (en) Process for preparing novel intermediates and aminopiperazine derivatives for use in synthetic applications
US2970147A (en) 3-hydroxy-nu-(heterocyclic-ethyl)-morphinans
US4005090A (en) 8-(β-AMINOETHYL)ERGOLINES-I
SU1650007A3 (en) Method of producing 1-[3-mercapto-(2s)-methylpropionil]-pyrrolidin-(2s) carbonic acid
SU786902A3 (en) Method of preparing 6-amino-2&#39;,3&#39;,5&#39;,6&#39;-tetrahydro-spiro-/penam-2,4&#39;-/4h/thio/pyran/-3-carboxylic acid or its ester
US4563464A (en) 2-Azabicyclo(2.2.2)octane derivatives and their use as immunosuppressive agents
KR940002828B1 (en) 2-oxo-1-oxa-8-azaspiro£4,5|decan derivatives
DE3915950A1 (en) 8 (ALPHA) ACYLAMINO ERGOLINE, THEIR PRODUCTION AND USE AS A MEDICINAL PRODUCT
Shaw et al. Indole Carboxamidines and Aminomethylindoles as Antimetabolites of Serotonin
US4284557A (en) Intermediate racemates for the preparation of biotin and a process for their preparation
US4320056A (en) Certain thia-diazatricyclo[3,3,3,08,11 ]tridecanes, and their preparation
SE460969B (en) APOVINCAMIC ACID DERIVATIVES, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES
KR920010074B1 (en) Process for preparing ergoline derivatives
KR20010030637A (en) New process for producing aminopiperazine derivatives
US6355804B1 (en) Process for producing piperidinecarboxylic acid amide derivatives
NO154635B (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ERGOTAL KALOIDS.
US4382031A (en) Intermediates for the preparation of biotin
GB1593410A (en) N-substituted-6,7-dialkoxy-1,2,3,4-tetrahydro-1-isoquinoline acetamides
US5929240A (en) Process and intermediates for preparing naphthyridonecarboxylic acid salts